APO Research
Talk to an analyst

APO RESEARCH · REPORT

DTaP and Tdap Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global DTaP and Tdap Vaccines Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchDTaP and Tdap Vaccines Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal DTaP and Tdap Vaccines Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal DTaP and Tdap Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DTaP and Tdap Vaccines Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal DTaP and Tdap Vaccines Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global DTaP and Tdap Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the DTaP and Tdap Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the DTaP and Tdap Vaccines market include Johnson & Johnson, Novartis AG, Lanzhou Institute of Biological Products Co., Ltd, Pfizer Inc, GlaxoSmithKline, AstraZeneca, Seqirus, Sanofi Pasteur and Protein Sciences Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DTaP and Tdap Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DTaP and Tdap Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DTaP and Tdap Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DTaP and Tdap Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

DTaP and Tdap Vaccines Segment by Company

Johnson & Johnson

Novartis AG

Lanzhou Institute of Biological Products Co., Ltd

Pfizer Inc

GlaxoSmithKline

AstraZeneca

Seqirus

Sanofi Pasteur

Protein Sciences Corporation

Merck Sharp & Dohme Corp

Emergent BioSolutions Inc

Astellas Pharma US, Inc

DTaP and Tdap Vaccines Segment by Type

Tdap

DTaP

Td

DTaP and Tdap Vaccines Segment by Application

Adult

Pediatric

DTaP and Tdap Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global DTaP and Tdap Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions DTaP and Tdap Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DTaP and Tdap Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze DTaP and Tdap Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTaP and Tdap Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DTaP and Tdap Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTaP and Tdap Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DTaP and Tdap Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DTaP and Tdap Vaccines industry.

Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of DTaP and Tdap Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of DTaP and Tdap Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DTaP and Tdap Vaccines Industry Trends Table 2. DTaP and Tdap Vaccines Industry Drivers Table 3. DTaP and Tdap Vaccines Industry Opportunities and Challenges Table 4. DTaP and Tdap Vaccines Industry Restraints Table 5. Global DTaP and Tdap Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DTaP and Tdap Vaccines Revenue Share by Company (2021-2026) Table 7. Global DTaP and Tdap Vaccines Sales Volume by Company (W Units) & (2021-2026) Table 8. Global DTaP and Tdap Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global DTaP and Tdap Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global DTaP and Tdap Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global DTaP and Tdap Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global DTaP and Tdap Vaccines Company, Product Type & Application Table 13. Global DTaP and Tdap Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global DTaP and Tdap Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tdap Table 18. Significant Companies of DTaP Table 19. Significant Companies of Td Table 20. Global DTaP and Tdap Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global DTaP and Tdap Vaccines Sales Volume by Type (2021-2026) & (W Units) Table 22. Global DTaP and Tdap Vaccines Sales Volume by Type (2027-2032) & (W Units) Table 23. Global DTaP and Tdap Vaccines Sales Volume Share by Type (2021-2026) Table 24. Global DTaP and Tdap Vaccines Sales Volume Share by Type (2027-2032) Table 25. Global DTaP and Tdap Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global DTaP and Tdap Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global DTaP and Tdap Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global DTaP and Tdap Vaccines Sales Value Share by Type (2021-2026) Table 29. Global DTaP and Tdap Vaccines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Adult Table 31. Significant Companies of Pediatric Table 32. Global DTaP and Tdap Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 33. Global DTaP and Tdap Vaccines Sales Volume by Application (2021-2026) & (W Units) Table 34. Global DTaP and Tdap Vaccines Sales Volume by Application (2027-2032) & (W Units) Table 35. Global DTaP and Tdap Vaccines Sales Volume Share by Application (2021-2026) Table 36. Global DTaP and Tdap Vaccines Sales Volume Share by Application (2027-2032) Table 37. Global DTaP and Tdap Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global DTaP and Tdap Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global DTaP and Tdap Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global DTaP and Tdap Vaccines Sales Value Share by Application (2021-2026) Table 41. Global DTaP and Tdap Vaccines Sales Value Share by Application (2027-2032) Table 42. Global DTaP and Tdap Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 43. Global DTaP and Tdap Vaccines Sales by Region (2021-2026) & (W Units) Table 44. Global DTaP and Tdap Vaccines Sales Market Share by Region (2021-2026) Table 45. Global DTaP and Tdap Vaccines Sales by Region (2027-2032) & (W Units) Table 46. Global DTaP and Tdap Vaccines Sales Market Share by Region (2027-2032) Table 47. Global DTaP and Tdap Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global DTaP and Tdap Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global DTaP and Tdap Vaccines Sales Value Share by Region (2021-2026) Table 50. Global DTaP and Tdap Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global DTaP and Tdap Vaccines Sales Value Share by Region (2027-2032) Table 52. Global DTaP and Tdap Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global DTaP and Tdap Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global DTaP and Tdap Vaccines Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Global DTaP and Tdap Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 57. Global DTaP and Tdap Vaccines Sales Market Share by Country (2021-2026) Table 58. Global DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 59. Global DTaP and Tdap Vaccines Sales Market Share by Country (2027-2032) Table 60. Global DTaP and Tdap Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global DTaP and Tdap Vaccines Sales Value Market Share by Country (2021-2026) Table 62. Global DTaP and Tdap Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global DTaP and Tdap Vaccines Sales Value Market Share by Country (2027-2032) Table 64. Johnson & Johnson Company Information Table 65. Johnson & Johnson Business Overview Table 66. Johnson & Johnson DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio Table 68. Johnson & Johnson Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis AG DTaP and Tdap Vaccines Product Portfolio Table 73. Novartis AG Recent Development Table 74. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 75. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 76. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio Table 78. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 79. Pfizer Inc Company Information Table 80. Pfizer Inc Business Overview Table 81. Pfizer Inc DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Pfizer Inc DTaP and Tdap Vaccines Product Portfolio Table 83. Pfizer Inc Recent Development Table 84. GlaxoSmithKline Company Information Table 85. GlaxoSmithKline Business Overview Table 86. GlaxoSmithKline DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio Table 88. GlaxoSmithKline Recent Development Table 89. AstraZeneca Company Information Table 90. AstraZeneca Business Overview Table 91. AstraZeneca DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. AstraZeneca DTaP and Tdap Vaccines Product Portfolio Table 93. AstraZeneca Recent Development Table 94. Seqirus Company Information Table 95. Seqirus Business Overview Table 96. Seqirus DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Seqirus DTaP and Tdap Vaccines Product Portfolio Table 98. Seqirus Recent Development Table 99. Sanofi Pasteur Company Information Table 100. Sanofi Pasteur Business Overview Table 101. Sanofi Pasteur DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio Table 103. Sanofi Pasteur Recent Development Table 104. Protein Sciences Corporation Company Information Table 105. Protein Sciences Corporation Business Overview Table 106. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio Table 108. Protein Sciences Corporation Recent Development Table 109. Merck Sharp & Dohme Corp Company Information Table 110. Merck Sharp & Dohme Corp Business Overview Table 111. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio Table 113. Merck Sharp & Dohme Corp Recent Development Table 114. Emergent BioSolutions Inc Company Information Table 115. Emergent BioSolutions Inc Business Overview Table 116. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio Table 118. Emergent BioSolutions Inc Recent Development Table 119. Astellas Pharma US, Inc Company Information Table 120. Astellas Pharma US, Inc Business Overview Table 121. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio Table 123. Astellas Pharma US, Inc Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. DTaP and Tdap Vaccines Distributors List Table 127. DTaP and Tdap Vaccines Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. DTaP and Tdap Vaccines Product Image Figure 2. Global DTaP and Tdap Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DTaP and Tdap Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global DTaP and Tdap Vaccines Sales (2021-2032) & (W Units) Figure 5. Global DTaP and Tdap Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global DTaP and Tdap Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tdap Image Figure 10. DTaP Image Figure 11. Td Image Figure 12. Global DTaP and Tdap Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global DTaP and Tdap Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global DTaP and Tdap Vaccines Sales Volume Share by Type (2021-2032) Figure 15. Global DTaP and Tdap Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global DTaP and Tdap Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global DTaP and Tdap Vaccines Sales Value Share by Type (2021-2032) Figure 18. Adult Image Figure 19. Pediatric Image Figure 20. Global DTaP and Tdap Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 21. Global DTaP and Tdap Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global DTaP and Tdap Vaccines Sales Volume Share by Application (2021-2032) Figure 23. Global DTaP and Tdap Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global DTaP and Tdap Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global DTaP and Tdap Vaccines Sales Value Share by Application (2021-2032) Figure 26. Global DTaP and Tdap Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 27. Global DTaP and Tdap Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global DTaP and Tdap Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global DTaP and Tdap Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America DTaP and Tdap Vaccines Sales Value (2021-2032) & (US$ Million) Figure 31. North America DTaP and Tdap Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe DTaP and Tdap Vaccines Sales Value (2021-2032) & (US$ Million) Figure 33. Europe DTaP and Tdap Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific DTaP and Tdap Vaccines Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific DTaP and Tdap Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America DTaP and Tdap Vaccines Sales Value (2021-2032) & (US$ Million) Figure 37. South America DTaP and Tdap Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa DTaP and Tdap Vaccines Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa DTaP and Tdap Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. DTaP and Tdap Vaccines Value Chain Figure 125. Manufacturing Cost Structure Figure 126. DTaP and Tdap Vaccines Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tdap
  • DTaP
  • Td
Applications
  • Adult
  • Pediatric
Companies covered
  • Johnson & Johnson
  • Novartis AG
  • Lanzhou Institute of Biological Products Co., Ltd
  • Pfizer Inc
  • GlaxoSmithKline
  • AstraZeneca
  • Seqirus
  • Sanofi Pasteur
  • Protein Sciences Corporation
  • Merck Sharp & Dohme Corp
  • Emergent BioSolutions Inc
  • Astellas Pharma US, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DTaP and Tdap Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global DTaP and Tdap Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global DTaP and Tdap Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 DTaP and Tdap Vaccines Market Dynamics
  1. 2.1 DTaP and Tdap Vaccines Industry Trends
  2. 2.2 DTaP and Tdap Vaccines Industry Drivers
  3. 2.3 DTaP and Tdap Vaccines Industry Opportunities and Challenges
  4. 2.4 DTaP and Tdap Vaccines Industry Restraints
3 DTaP and Tdap Vaccines Market by Company
  1. 3.1 Global DTaP and Tdap Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global DTaP and Tdap Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global DTaP and Tdap Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global DTaP and Tdap Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global DTaP and Tdap Vaccines Company Ranking (2024-2026)
  6. 3.6 Global DTaP and Tdap Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global DTaP and Tdap Vaccines Company Product Type and Application
  8. 3.8 Global DTaP and Tdap Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global DTaP and Tdap Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 DTaP and Tdap Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 DTaP and Tdap Vaccines Market by Type
  1. 4.1 DTaP and Tdap Vaccines Type Introduction
  2. 4.1.1 Tdap
  3. 4.1.2 DTaP
  4. 4.1.3 Td
  5. 4.2 Global DTaP and Tdap Vaccines Sales Volume by Type
  6. 4.2.1 Global DTaP and Tdap Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global DTaP and Tdap Vaccines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global DTaP and Tdap Vaccines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global DTaP and Tdap Vaccines Sales Value by Type
  10. 4.3.1 Global DTaP and Tdap Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global DTaP and Tdap Vaccines Sales Value by Type (2021-2032)
  12. 4.3.3 Global DTaP and Tdap Vaccines Sales Value Share by Type (2021-2032)
5 DTaP and Tdap Vaccines Market by Application
  1. 5.1 DTaP and Tdap Vaccines Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global DTaP and Tdap Vaccines Sales Volume by Application
  5. 5.2.1 Global DTaP and Tdap Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global DTaP and Tdap Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global DTaP and Tdap Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global DTaP and Tdap Vaccines Sales Value by Application
  9. 5.3.1 Global DTaP and Tdap Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global DTaP and Tdap Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global DTaP and Tdap Vaccines Sales Value Share by Application (2021-2032)
6 DTaP and Tdap Vaccines Regional Sales and Value Analysis
  1. 6.1 Global DTaP and Tdap Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DTaP and Tdap Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global DTaP and Tdap Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global DTaP and Tdap Vaccines Sales by Region (2027-2032)
  5. 6.3 Global DTaP and Tdap Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global DTaP and Tdap Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global DTaP and Tdap Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global DTaP and Tdap Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global DTaP and Tdap Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America DTaP and Tdap Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America DTaP and Tdap Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe DTaP and Tdap Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe DTaP and Tdap Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific DTaP and Tdap Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific DTaP and Tdap Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America DTaP and Tdap Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America DTaP and Tdap Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa DTaP and Tdap Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa DTaP and Tdap Vaccines Sales Value Share by Country, 2025 VS 2032
7 DTaP and Tdap Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global DTaP and Tdap Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DTaP and Tdap Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global DTaP and Tdap Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global DTaP and Tdap Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global DTaP and Tdap Vaccines Sales by Country (2027-2032)
  6. 7.4 Global DTaP and Tdap Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global DTaP and Tdap Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global DTaP and Tdap Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt DTaP and Tdap Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt DTaP and Tdap Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt DTaP and Tdap Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG DTaP and Tdap Vaccines Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Lanzhou Institute of Biological Products Co., Ltd
  14. 8.3.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  15. 8.3.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  16. 8.3.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio
  18. 8.3.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc DTaP and Tdap Vaccines Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca DTaP and Tdap Vaccines Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Seqirus
  38. 8.7.1 Seqirus Company Information
  39. 8.7.2 Seqirus Business Overview
  40. 8.7.3 Seqirus DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Seqirus DTaP and Tdap Vaccines Product Portfolio
  42. 8.7.5 Seqirus Recent Developments
  43. 8.8 Sanofi Pasteur
  44. 8.8.1 Sanofi Pasteur Company Information
  45. 8.8.2 Sanofi Pasteur Business Overview
  46. 8.8.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio
  48. 8.8.5 Sanofi Pasteur Recent Developments
  49. 8.9 Protein Sciences Corporation
  50. 8.9.1 Protein Sciences Corporation Company Information
  51. 8.9.2 Protein Sciences Corporation Business Overview
  52. 8.9.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio
  54. 8.9.5 Protein Sciences Corporation Recent Developments
  55. 8.10 Merck Sharp & Dohme Corp
  56. 8.10.1 Merck Sharp & Dohme Corp Company Information
  57. 8.10.2 Merck Sharp & Dohme Corp Business Overview
  58. 8.10.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio
  60. 8.10.5 Merck Sharp & Dohme Corp Recent Developments
  61. 8.11 Emergent BioSolutions Inc
  62. 8.11.1 Emergent BioSolutions Inc Company Information
  63. 8.11.2 Emergent BioSolutions Inc Business Overview
  64. 8.11.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio
  66. 8.11.5 Emergent BioSolutions Inc Recent Developments
  67. 8.12 Astellas Pharma US, Inc
  68. 8.12.1 Astellas Pharma US, Inc Company Information
  69. 8.12.2 Astellas Pharma US, Inc Business Overview
  70. 8.12.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio
  72. 8.12.5 Astellas Pharma US, Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DTaP and Tdap Vaccines Value Chain Analysis
  2. 9.1.1 DTaP and Tdap Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DTaP and Tdap Vaccines Sales Mode & Process
  6. 9.2 DTaP and Tdap Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DTaP and Tdap Vaccines Distributors
  9. 9.2.3 DTaP and Tdap Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst